Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Wake Forest University Health Sciences
Status
Completed
NCT ID
NCT03475186
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
Intervention
Ramipril
Condition
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
Investigators
Glenn Lesser, MD

See list of participating sites